New York, Jan 6, 2026, 12:38 (EST) — Regular session
- Regencell Bioscience Holdings shares rise about 18% in midday trade after a wide intraday swing
- Company site shows no new press release since its Oct. 31 annual report filing
- Investors look for any fresh filing or statement, with Jan. 16 options expiry next on the calendar
Regencell Bioscience Holdings Ltd shares rose 18.3% to $31.99 on Tuesday, after touching $34.40 earlier and sliding as low as $26.60. The Nasdaq-listed stock was last up $4.95 from Monday’s close of $27.04, with about 850,000 shares traded.
The move keeps the Hong Kong-based bioscience company on momentum traders’ radar at the start of 2026, after a run of outsized daily swings. In small, lightly followed stocks, rapid price shifts can draw more short-term flow — and just as quickly reverse when liquidity thins.
Regencell’s investor-relations site has not posted a new press release since Oct. 31, when it said it filed its Form 20-F annual report — the disclosure foreign companies file with U.S. regulators. Regencell Bioscience –
In that filing, Regencell said it received correspondence and a subpoena from the U.S. Department of Justice after volatility in its shares, and that the DOJ was investigating trading in the stock. The company also warned there was “substantial doubt” about its ability to continue as a going concern — accounting language that flags it may need more funding to keep operating — and reported a net loss of $3.58 million for the year ended June 30, 2025. SEC
Regencell was also among the biggest gainers in U.S. premarket trade on Monday, rising about 16% before the bell, as traders chased volatile movers, Barron’s reported.
Tuesday’s $7.80 intraday range has widened the gap between buyers and sellers, a setup that can magnify jumps when orders thin out. The shares have pushed back above $30, with the day’s high near $34 back in view.
But the swings cut both ways. Any update on the Justice Department probe, an equity raise to bolster cash, or a sudden drop in trading volume could hit the stock hard, and momentum trades often unwind as fast as they build.
